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ABSTRACT
Ganoderma a traditional Chinese medicine popularly used for complementary cancer therapy and longevity for centuries. The vast amount of study 
has been performed on the medicinal properties of Ganoderma lucidum. G. lucidum contains various compounds with a high grade of biological activity, 
which increase the immunity. Several of these substances belong to the triterpenoids and polysaccharides. Proteins, sterols, phenols, lipids, etc., are also 
present. Ganoderma triterpenes are important secondary metabolites of G. lucidum. Ganoderma triterpenes are limestone-tetracyclic terpenes which 
have been reported to possess antioxidant, antitumor, anti-human immunodeficiency virus, anticancer, anti-inflammation, cytotoxic, hepatoprotective, 
and neuroprotective activities. This review deals with most important triterpenes isolated from Ganoderma and their therapeutic effects.
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INTRODUCTION
Ganoderma is a wood-rotting mushroom with hard fruiting body 
and grows on decaying tree stumps or logs. Ganoderma is known by 
various popular names as “Reishi” in Japan, “Lingzhi” in China, and 
“Yeongji” in Korea. The taxonomical studies have reported about 300 
species which belong to genus Ganoderma and the majority of which 
are distributed in tropical regions. Species of Ganoderma are corky, 
tough, and thick. Ganoderma does not have the fleshy texture and thus 
do not qualify to be considered as edible mushrooms [1,2]. Some of the 
important species of Ganoderma on which most of the research work 
on medical aspects have been carried out are as follows: Ganoderma 
lucidum, G. sinensis, G. theaecolum, G. zonatum, G. applanatum, G. pfeifferi, 
G. tsugae, G. resinaceum, G. amboinense, G. colossum, G. formosanum, 
G. australe, and G. atrium. G. lucidum is the most commonly characterized 
medicinal mushroom of the genus Ganoderma [3-8]. The more weight of 
Ganoderma mushroom is due to its high water content up to 90%, which 
makes extracts of mushroom dehydrated powder and residual 10% 
of its mass consist of protein (10–40%), carbohydrate (3–28%), fiber 
(3–32%), fat (28%), and ash (8–10%). Besides, various other compounds 
such as provitamin D2 [9], C19 fatty acids [10], and essential nutrients 
such as copper and zinc [11] have also been found to be present. With 
the minerals potassium, calcium, phosphorous, magnesium, selenium, 
iron, zinc, and copper represent most of the mineral content [12,13]. 
Rex, 2014 [14], reported that G. lucidum contains about 72 μg Se/g of 
dry weight and thus can act as a good source of essential micronutrients 
like selenium. G. lucidum is found across the world and is considered 
as an effective supplement for the prevention and treatment of many 
diseases since ages. Triterpenes and polysaccharides from G. lucidum 
have been found to possess anti-inflammatory and antioxidant activity. 
The polysaccharide and the water extract from G. lucidum have shown 
to possess immune modulator and antitumor activities. In addition, 
G. lucidum have a wide variety of bioactive compounds such as terpenoids 
mostly triterpenoids, carbohydrates including polysaccharides and 
glycoproteins, steroids, phenolic compounds, nucleotides, and their 
derivatives. The proteins of Ganoderma mushroom contain different 
essential amino acids. Lysine and leucine represent the highest 
percentages. G. lucidum, also contains a large share of polyunsaturated 
fatty acids as compared to the total fatty acids, which are the highest 
contributors for the best human health [6,12].
Ganoderma has been generally admitted as nutritional supplement 
across the world due to its long-term safety and tolerance. G. lucidum 
possess a vast array of medicinal properties. The extremely important 
G. lucidum in oriental traditional medicine has been used as 
remedy against various chronic diseases such as antitumor [15,16], 
antioxidant [17], immunoregulation [18,19], hepatoprotection [20], 
hypoglycemic effect [21,22], antibacterial activity [23], reduction 
of blood cholesterol [24,25], inhibition of angiogenesis [26,27], 
antifibrotic activity [28], anti-human immunodeficiency virus (HIV) 
activity [29], and reduction of lower urinary tract symptoms [30]. The 
above bioactivities of Ganoderma have been found due to the important 
bioactive substances such as polysaccharides and triterpenoids. 
Despite the vast array of reported medicinal attributes of Ganoderma; 
however, the pathways and mechanisms of action of these bioactive 
substances from Ganoderma remain poorly defined. With further 
advancement in modern research technologies, clear and detailed 
insights into these pathways and mechanisms of action are becoming 
increasingly possible in which G. lucidum can influence the observed 
health benefits. Understanding these mechanisms could lead to 
more robust use of Ganoderma as an anticarcinogenic agent. With 
improvement in techniques, better separation and purification 
methods have proved very beneficial for the isolation and identification 
of bioactive substances from G. lucidum. However, modern researchers 
have primarily focused more on two active components, namely 
triterpenes and polysaccharides. In the foregoing account, emphasis 
has been given on the research work carried out by different scientists 
on major bioactive triterpenoids found in G. lucidum and other species 
of Ganoderma.
TRITERPENES
Triterpenes are biologically active compounds which contribute to 
the vast array of medicinal and health benefits of G. lucidum [12,31]. 
Triterpenes are a subtype of terpenes and are composed of six isoprene 
units. These isoprene units of terpenes usually form linear chains 
or ring-like structures. Ganoderic acids (GAs) represent a subtype 
of triterpenes with four cyclic and two linear isoprene units [32]. 
About 140 subtypes of GAs have been reported and identified from 
G. lucidum [33]. >130 triterpenoids (Lanostane type) have been isolated 
from fruiting bodies, spores, mycelia, and cultures of G. lucidum. They 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Mushroom Bioactive compound Bioactivity References
G. lucidum GA T Shows anticancer activity against lung: 95D, liver: 
KB-A-1: KB-3-1, cervix: SMMC7721, epidermis: HCT-116 
melanoma, HeLa colon: Ls174t, lung: A375, colon: LLC 
cell lines. It inhibited the growth and proliferation of 
these cancer cells
[41,42,120,121]
G. lucidum GA D It shows apoptotic activity against cervical: HeLa cell 
line and inhibited cell proliferation
[33,43,100]
G. lucidum GA F Shows cytotoxic activity [36,44-46,122,123]
G. lucidum GA Me It shows cytotoxic activity against breast: MDA-MB-231, 
lung: 95-D, colon: HCT-116, HCT-8 cell lines. It arrests 
cell cycle, targets p53, and inhibited cell proliferation, 
migration, invasion, and induced apoptosis
[91,124-128]
G. lucidum GA Mc It shows cytotoxic activity against lung: 95D, cervical: 
HeLa cell lines
[124,129]
G. lucidum Lucialdehydes A C Shows cytotoxic activity [45]
G. lucidum 3α, 22β-diacetoxy-7α hydroxyl 
-5α-lanost-8, 24E-dien-26-oic acid
It shows cytotoxic activity against lung: 95D, cervical: 
HeLa cell lines
[130]
G. lucidum GA MK It shows cytotoxic activity against lung: 95D, cervical: 
HeLa cell lines
[130,131]
G. lucidum GA Mf/S It shows cytotoxic activity against lung: 95D, cervical: 
HeLa cell lines
[124,129]
G. lucidum GA R It shows cytotoxic activity against lung: 95D, cervical: 
HeLa cell lines
[130]
G. lucidum Colossolactone H Shows apoptotic activity [132]
G. lucidum Ganodermanontetrol Shows cytotoxic activity [133]
G. lucidum Ganodermanontriol It inhibited cell proliferation in the breast: MDA-MB-231, 
colon: HCT-116, HT-29 cell lines
[134]
G. lucidum 3β, 24S, 25R, 26-tetradroxy-7α-methoxy 
-8-ene-lanost-ol
Shows cytotoxic activity [133]
G. lucidum 12α-methoxy-ganodermanondiol Shows cytotoxic activity [133]
G. lucidum 15β-hydroxy-lucidumol A Shows cytotoxic activity [133]
G. lucidum 15α-hydroxy-ganodermanontriol Shows cytotoxic activity [133]
G. lucidum Lucidinic acid, O and lucidinic lactones Inhibited HIV Type 1 reverse transcriptase [87]
G. lucidum Ganodermic acid S Induction of platelet aggregation [135]
G. lucidum 26-oxygenosterols, ganoderol A, 
ganoderol B, ganoderol A, and GA Y
Lowering of blood cholesterol [136]
G. pfeifferi Ganoderone A Inhibitory activity against herpes simplex virus [137]
G. lucidum Lucialdeyde B Shows cytotoxic activity [45]
G. lucidum 15α, 26 dihydroxy-5α-lanostane- 
7, 9, 24(E)-triene-3-one
It shows cytotoxic activity against human HeLa cervical 
cancer cell line
[95]
G. lucidum 23S-hydroxy-3, 7, 11, 
15- tetraoxolanost-8, 24E-diene-26-oic 
acid
It shows cytotoxic activity against HeLa, p388, 
SGC-7901, BEL-7402 human cancer cell lines
[48]
G. lucidum 12β-Acetoxy-3β-hydroxy- 7,11,15,23 
-tetraoxolanost- 8,20 E‑diene-26-oic acid
It shows cytotoxic activity against HeLa, p388, 
SGC-7901, BEL-7402 human cancer cell lines
[48]
G. lucidum GAs γ, δ,ε,ζ,η Studied against Meth-A and LLC tumor cell lines [36]
G. sinensis GA Jc Showed selective inhibition against HL-60 cells [9]
G. lucidum Ganoderiol E Shows cytotoxic activity against MCF-7 cells [138]
G. lucidum GA A Strong cytotoxic activity against breast: MDA-MB-231. 
Inhibited growth and invasive behavior of breast cancer 
cells
[100,110,123]
G. lucidum GA, H Strong cytotoxic activity against breast: MDA-MB-231. 
Inhibited growth and invasive behavior of breast cancer 
cells
[123]
G. lucidum GA C1 Strong cytotoxic activity [45]
G. pfeifferi Lucialdehyde D Strong cytotoxic activity [137]
G. lucidum Lucialdehyde E Strong cytotoxic activity [139]
G. tsugae Tsugaric acid A Significant activity against T-24 and HT-3 cells [140]
G. tsugae Tsugarioside A Activity against T-24 cells [51]
G. tsugae 3β-Hydroxy-5α-lanosta-8,24-diene - 
21-oic acid
Activity against CaSKi cells [51]
G. amboinense GA X Activity against liver: HuH-7, colon: HCT-116 cell lines 
and inhibits topoisomerase and induces apoptosis of 
cancer cells
[68]
G. resinaceum 3α-(3-Hydroxy-5- methoxy-3-methyl-1,5 
dioxopentyloxy)-24 methylene-5α- 
lanost-8-en-21-oic acid
Significant cytotoxic activity [47]
Table 1: Triterpenoids from Ganoderma and their bioactivity
(Contd...)
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have molecular weights ranging from 400 to 600 KDa. Triterpenes 
isolated from Ganoderma species show remarkable therapeutic and 
pharmacological properties on a number of human diseases including 
cancer pharmacological properties [1,16,18,20,31,33]. The triterpene 
extracts of G. lucidum are known to induce apoptosis of multiple human 
cancer cell lines [16]. However, the cytotoxic activity of triterpenes 
varied significantly across different subtypes of triterpenes [16]. Most 
triterpenoids extracted and identified from Ganoderma have shown 
robust biological activities (Table 1). The GAs isolated from Ganoderma 
have shown antiviral, anticancer, antioxidant, hepatoprotective, 
cytotoxic, antiplatelet aggregation, and inhibition of histamine release 
and hypocholesterolemic activities [7,34-40]. The most abundant 
triterpenic acid from G. lucidum is GA T which shows significant 
anticancer activity both in vivo and in vitro experiments [41,42]. 
GA has been found to inhibit tumor invasion by inhibiting matrix 
metalloproteinase (MMP)-9 expressions [42]. Another triterpenic 
acid GA D has been shown to directly bind to 14-3-3ζ protein [43] and 
this binding may contribute to the facilitation of apoptosis observed 
in human epithelial cell line (HeLa) cell [43]. Ganoderiol F (GA-F) a 
tetracyclic triterpene found in Ganoderma lucidum [36,44] has shown 
Mushroom Bioactive compound Bioactivity References
G. lucidum GA E Cytotoxic activity against Hep G2Hep G2, 2,15 and P-338 
cell lines
[74,122]
G. lucidum Lucidinic acid N Cytotoxic activity against, Hep G2Hep G2, 2,15, P-338, 
and leukemia: HL 60 cell lines
[74,141,142]
G. lucidum Lucidinic acid A Cytotoxic activity against Hep G2Hep G2, 2, 15, P-338, 
leukemia: HL 60 cell lines and decreases cell population 
growth, cell cycle arrest of these cell lines
[142,143]
G. lucidum Lucidinic acid B Induces apoptosis in leukemia: HL 60, liver: HepG2, 
lymphoma: CA46 cell lines
[142,144]
G. lucidum Lucidinic acid C Decreases cell population growth, cell cycle arrest of 
leukemia: HL 60 cell lines
[142]
G. lucidum Ethyl lucidenates A Cytotoxic activity against HL-60 and CA 46 cancer cell 
lines
[129]
G. applanatum Applanoxidic acid A, applanoxidic acid B, 
applanoxidic acid C, applanoxidic acid D
Antitumor promoters [50]
G. zonatum GA γ Cytotoxic activity against liver and lung cancers [145]
G. applanatum Applanoxidic acid G, applanoxidic acid F, 
applanoxidic acid A, applanoxidic acid C
Inhibition of viability and growth of the HL-60 cell lines [50,146]
G. australe Austrolactone, australic acid Inhibition of viability and growth of the HL-60 cell lines [147]
G. colossum Colossolactone E colossolactone G, 
colossolactone VIII, colossolactone V, 
colossolactone VI, colossolactone VII
Inhibitory activity against HIV-1 protease [88,148]
G. lucidum Ganolucidic acid A Inhibitory activity against HIV-1 protease [149]
G. lucidum GA β Inhibitory activity against HIV- 1 protease [86]
G. lucidum Lucidumol B Inhibitory activity against HIV- 1 protease [86]
G. lucidum GA B Hepatoprotective activity [100]
G. lucidum Ganosporeric acid A Hepatoprotective activity [102]
G. lucidum t‑Butyl lucidenate B Antiobesity activity [150]
G. lucidum Lucidadiol Cytotoxic activity against human HeLa cervical cancer [113]
G. lucidum Ganoderiol F Cytotoxic activity against human HeLa cervical cancer, 
lung: LLC Meth A, sarcoma: Sarcoma-180, carcinoma: 
T-47D, lung: LLC cell lines. Active anti-HIV-1 agent
[36,46,138]
G. theaecolum GA XL1 GA XL2 20-hydroxy-GA AM1  
Ganoderenic acid AM1 ganodericin C
Hepatoprotective activity [103]
G. pfeifferi Ganoderone C Antiviral activity against influenza virus A [137]
G. pfeifferi Lucialdehyde B Antiviral activity against herpes simplex virus, antiviral 
activity against influenza virus A
[137]
G. pfeifferi Applanoxidic acid G Antiviral activity against influenza virus A [151]
G.pfeifferi Lucidadiol Antiviral activity against influenza virus A [151]
G. lucidum Lucialdehyde C Shows cytotoxic activity [45]
G. lucidum Ganodermenonol Shows cytotoxic activity [152]
G. lucidum Ganodermanondiol Shows cytotoxic activity and inhibitory activity against 
HIV-1 protease
[107]
G. lucidum GA DM1 and DM2 Inhibition of the proliferation and metastasis of the 
aggressive human prostate cancer cell line PC3
[70,153]
G. lucidum Methyl ganoderate B Neurotrophic activity [100,110]
G. lucidum Methyl ganoderate A Neurotrophic activity [100]
G. lucidum GA S1 Neurotrophic activity [112]
G. lucidum GA T-Q Neurotrophic activity [111]
G. lucidum n-Butyl ganoderate H Neurotrophic activity [114]
G. lucidum Methyl ganoderate acetonide Neurotrophic activity [114] 
G. lucidum Lucidadiol Neurotrophic activity [113]
G. lucidum Ganodermanondiol Neurotrophic activity [107]
G. lucidum 4, 4, 14α-trimethyl-5α-chol-7,9 (11)- 
diene-3-oxo-24-oic-acid
Neurotrophic activity [112]
HeLa: Human epithelial cell line, HepG2: Hydroperoxide in human hepatic, HIV: Human immunodeficiency virus, G. lucidum: Ganoderma lucidum, GA: Ganoderic acids
Table 1: (Continued)
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significant cytotoxic activity against Sarcoma-180, Lewis lung carcinoma 
(LLC), Meth-A and T-47D cancer cell lines [36,45]. GA-F has also been 
demonstrated in vivo in rats with LLC tumor cells [46]. The other forms 
of the isolated triterpenes from Ganoderma lucidum have been reported 
to show cytotoxic activity in the p338, HeLa, human hepatoma cell line 
(BEL-7402), and human gastric cancer cell line (SGC-7901) [47,48]. 
Recently, Hsu et al., 2018 [49], tested a new atheroprotective effect 
of G. lucidum, an arterial condition which is associated with chronic 
oxidative stress and inflammation, using a carotid artery ligation mouse 
model. In this study, the ligation of the artery generated disturbed blood 
flow, a critical atherogenic factor with no cure currently. These authors 
studied that G. lucidum protected arteries from disturbed flow-induced 
atherogenesis and the triterpenoid fraction is the critical constituents 
for these effects. Ganoderma triterpenoids alleviated oxidative stress 
and inflammation, thereby preventing neointimal hyperplasia in 
the ligated arteries through daily oral dosage after 2 weeks. Specific 
triterpenes or a mixture of triterpenes have been isolated and identified 
from G. lucidum and other species of Ganoderma with various health 
benefits, the results of which have been published. The various health 
benefits of Ganoderma triterpenes are as follows.
Anticancer activities
The triterpene extracts identified from G. lucidum and other 
Ganoderma species have shown anticancer property under in vivo 
conditions [12,33,50-52]. The carcinogenic effects shown by various 
types of extracts from G. lucidum include various cancer cell lines 
(breast, colon, lung, pancreas, prostate, and skin) [12,52]. The known 
mechanisms through which the extracts of G. lucidum exhibit anticancer 
activities include direct inhibition of cell proliferation through cancer-
specific cell cycle arrest and apoptosis [41,53-55]. G. lucidum extracts, 
in addition, can lead to downregulation of cell cycle-associated proteins, 
resulting in cell cycle arrest [54,56,57]. Studies of the triterpene 
extracts from G. lucidum have shown that these extracts can arrest the 
cell cycle at the G1 phase [54,55]. The mechanism for this inhibition of 
cell cycle at G1 phase is by the downregulation of cyclin D1 through the 
modulation of the β-catenin pathways [58]. Cyclin D1 is the key regulator 
of cyclin-dependent kinase which is very important for the transition of 
G1/S phase of the cell cycle [59]. About 30% of colon cancer has an 
overexpression of cyclin D1, due to the abnormal β-catenin signaling 
pathway [60]. The triterpene from G. lucidum, ganodermanontriol has 
been found to inhibit the proliferation of human colorectal carcinoma 
cell lines (HCT116 and HT-29) by inhibiting the expression of β-catenin, 
thus controlled levels of cyclin D1 is expressed [54]. The triterpene 
extracts from Ganoderma can also cause inhibition of G2/M transition, 
apart from inhibiting G1 phase of cell cycle [38]. It has been studied 
that the triterpene extract of Ganoderma can suppress the activity of 
protein kinase C (PKC), leading to a prolonged G2 phase, by treatment 
with the triterpene-enriched ethanol soluble fractions (WEES-G6). PKC 
is selectively activated during G2 phase of the cell cycle and belongs to 
the class of serine-threonine protein kinases [61]. During the G2 phase 
of the cell cycle, PKC has been found to be involved in the regulation of 
nuclear disassembly [62]. Various studies have reported that the use 
of PKC inhibitors can arrest the G2 phase of the cell cycle [63,64]. In 
addition, the level of cycling B, a kinase, which is responsible for the 
transition from G2 to M phase, is reduced by WEES-G6 [38]. Due to the 
activity of WEES-G6, the c-Jun N-terminal kinase (JNK) and p38 kinase, 
both of which are mitogen-activated protein kinase which responded 
to cellular stress are activated [38]. JNK is considered very critical 
regulator of transcription which can activate tumor suppressors such 
as p53 [65-67]. Johnson and Lapadat [67] observed cell cycle arrest 
in triterpene-treated human hepatoma (HuH-7) carcinoma, but no 
effect has been seen in a normal human liver cell line, which further 
supports the use of triterpenes as therapeutic anticancer agent. Jiang 
et al., 2004 [52], reported that G. lucidum suppress the growth of 
breast cancer cells through the inhibition of Akt/NF-Kappa B signaling. 
How the triterpene-induced G2 phase cell cycle arrest occurs. Li 
et al., 2005 [68], identified the inhibition of DNA synthesis through the 
inhibition of topoisomerase as the possible mechanism of GA X-induced 
cell cycle arrest. Tang et al., 2006 [41], observed that GA from G. lucidum 
mycelia induces mitochondria-mediated apoptosis in lung cancer cells. 
Similarly, Chen et al., 2010 [42], revealed that GA T from G. lucidum 
inhibits the tumor growth through inhibition of MMP expression.
A recent study by researchers reported that gold nanoparticles 
(Au-NPs) synthesized from G. lucidum and then conjugated with drug 
doxorubicin show robust and significant anticancer drug accumulation 
and cytotoxic activity against MCF-7-doxbreast cancer cell line. Au-
NPs efficiently inhibited the growth of MCF-7-doxbreast cancer cell 
line at higher concentration (400 μM/ml) by 97%. mRNA expression 
of ABCB1 gene and CDNA synthesized from human breast cancer cell 
line (MCF-7) showed reduced expression. It is important to conclude 
that the pharmacological activity of G. lucidum exhibits the anticancer 
activity of newly synthesized Au-NPs conjugated with drug doxorubicin. 
However, further research is required under in vivo conditions to report 
toxicity if any, due to newly synthesized Au-NPs. Au-NPs synthesized 
from G. lucidum conjugated with drug doxorubicin could prove as 
possible and strong source of drug delivery for anticancer inducing 
drug preparation which can benefit treatment of breast cancers [69].
Cytotoxic activities
The triterpene extracts identified from G. lucidum have been to show 
cytotoxic effects under in vitro conditions (on cancer cell lines) [12]. 
Various cytotoxic compounds from G. lucidum have been found to 
trigger apoptosis, leading to programmed cell death [52,53]. The 
triterpenes from G. lucidum also observe to cause apoptosis of various 
cancer cell lines, and this has been found to be due to the increase of 
proapoptotic proteins and decrease of antiapoptotic proteins [41,53]. 
The structure–activity relationship of GA-DM was investigated and it 
was shown to inhibit the proliferation of the aggressive human prostate 
cancer cell line PC3 [70].
The mechanisms by which triterpenes from G. lucidum induce apoptosis 
in human cancer cell lines include mitochondria-dependent pathway 
followed by activation of caspase cascade [70,71]. The mitochondrial-
dependent apoptotic pathway also known as intrinsic apoptotic 
pathway involves the decrease in mitochondrial potential followed 
by the release of cytochrome c from the mitochondria [72,73]. The 
cytochrome c which is released from the mitochondria into the cytosol 
is known to trigger the caspase cascade which leads to apoptosis. This 
caspase cascade involves caspase 9 and caspase 3 which have been 
studied to have higher expressions in different human cancer cell lines 
when treated with the triterpenes extract from G. lucidum [41,71,74]. 
The release of cytochrome c depends on the ratio of Bax/Bcl-2 
balance [75]. It has also been observed that when the ratio of Bax/Bcl-
2 is increased, apoptosis is triggered. The Bcl-2 family proteins can be 
either proapoptotic or antiapoptotic. Bcl-2 associated X protein (Bax) 
and Bcl-2 associated death promoter (Bad) are proapoptotic while as 
Bcl-2 is antiapoptotic. Various studies have revealed that during the 
treatment of different human cancer cell lines with the triterpenes 
of G. lucidum, the ratio of Bax/Bcl-2 is increased which, therefore, 
increases Bax expression while downregulating Bcl-2 expression [71]. 
Liu et al., 2012 [70], observed cytotoxic and proapoptotic effect of GA 
derivatives on human cervical cancer cells under in vitro conditions.
Antioxidant activity
The major contributor to increased cancer risk is known to be the 
oxidative stress. Reactive oxygen species (ROS) and free radicals are 
produced as by-products of metabolic processes involving redox 
enzymes and electron transfer during bioenergetics, as well as due to 
exposure to some exogenous chemicals [76]. Free radicals and ROS can 
damage cells and tissues by the process of oxidation and long-term 
accumulation of such damage due to free radicals and ROS causes aging 
and various age-associated diseases [77]. ROS and free radicals have 
the potential to cause damage to proteins and DNA within cells, leading 
to oxidative stress, which can be countered by antioxidative enzymes 
and repair mechanisms. However, it has been observed that excessive 
oxidative stress can override the innate protective system, leading to a 
variety of physiological disorders including cancer [78]. These cancer 
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cells further contribute to cancer progression by generating increased 
levels of free radicals relative to normal cells [78]. Various studies 
have suggested that this cancer-causing damage might be reduced or 
prevented with the help of antioxidants from the extracts of Ganoderma 
species [78,79].
Various other studies have also shown that the triterpene extracts of 
G. lucidum have antioxidant activity and have the potential to reduce 
oxidative damage by directly scavenging free radicals generated in 
the cell due to the increase in the activity of superoxide dismutase 
and catalase which are enzymes involved in removing harmful free 
radicals and ROS [80,81]. Smina et al., 2011 [82,83], revealed in mice 
that triterpenes from G. lucidum showed antioxidant activity which may 
be due to increased activity of antioxidant enzymes and they further 
observed that total terpenes from G. lucidum prevent radiation-induced 
DNA damage and apoptosis in splenic lymphocytes of mice under in vitro 
conditions. In a recent study by Smina et al., 2016 [84], total triterpenes 
from G. lucidum were highly effective in reducing the levels of lipid 
peroxidation and protein oxidation to near normal values in both liver 
and brain tissues in Swiss albino mice under in vivo conditions. Total 
triterpenes, when administered under vivo conditions, were also found 
to be successful in restoring the antioxidant enzyme activities and 
glutathione level in liver and brain of irradiated mice. Administration 
of total triterpenes, before radiation exposure, significantly decreased 
the DNA strand breaks.
Anti-HIV activity
HIV, which induces a lethal and incurable condition known as acquired 
immunodeficiency syndrome (AIDS), is a highly infectious virus 
affecting an estimated 35 million people all over the world [85]. The 
treatment strategies for HIV, which are currently in use, involve 
delaying the progression of disease into AIDS [85]. Various compounds 
that exhibit inhibitory effects against AIDS have been identified from 
G. lucidum, and related species of Ganoderma such as triterpenes have 
shown anti-HIV-1 protease activity [22,86]. Mizushina et al., 1999 [87], 
observed the inhibition of HIV Type 1 transcriptase due to lucidinic 
acid and lucidinic lactones isolated from G. lucidum. el-Mekkawy et al., 
1998 [29], have assayed 13 compounds for anti-HIV activity isolated 
from G. lucidum. El Dine et al., 2008 [88], observed anti-HIV-1 protease 
activity of triterpenoids from G. colosseum. The inhibitory activity of 
triterpenoids isolated from Ganoderma species against HIV has also 
been reported by Cassels and Asencio, 2011 [89]. Various compounds 
out of these have shown anti-HIV-1 activity, which includes GA A 
which showed robust activity against HIV proteases. However, much-
extended research is to be carried out to ascertain a mechanistic basis 
for G. lucidum extracts and other species of Ganoderma as anti-HIV 
agents. In addition, determination of the structure–activity relationship 
between triterpenes from G. lucidum and HIV proteases must be 
performed as well.
Antimetastatic potential
Cancer metastasis is very complex phenomenon in which cancer 
cells split from the primary tumor cells and invade other tissues, 
thereby leading to the formation of secondary tumors. Cancer 
metastasis dramatically reduces the rate of survival and cure, when 
left untreated [90]. Several key proteins which are involved in 
metastasis of cancer may be regulated by triterpenes of G. lucidum 
and other species of Ganoderma [64,91]. MMP is a family of proteins 
which cause degradation of extracellular matrix and thereby promote 
cancer metastasis [32,92,93]. The triterpenoid GA-Me extracted from 
G. lucidum suppressed the invasion of 95-D, LLC, and HCT-116 metastatic 
cancer cell lines through inhibition of MMP-9 expression [75,94]. Chen 
et al. [95] revealed that GA T extracted from G. lucidum inhibits the 
tumor invasion through inhibition of MMP expression. Interleukin 
(IL-8) and various angiogenic factors such as vascular endothelial 
growth factor (VEGF) caused induction of angiogenesis and resulted 
in the promotion of metastasis [96]. It is further suggested that the 
expression of IL-8 is upregulated during oxidative stress, and therefore, 
overexpression of IL-8 is involved in the metastasis of breast cancer 
cell lines [97,98]. Studies have reported that oxidative-induced IL-8 
expression was reduced in breast cancer cell lines after treatment with 
triterpenoid extracts of G. lucidum [99].
Hepatoprotective activity
It has been studied that GA B isolated from Ganoderma species showed 
significant hepatoprotection property [100]. However, it was observed 
that when the doses of GA B were increased 10 times than the normal, it 
did not further reduce glutamic oxaloacetic transaminase and glutamic 
pyruvic transaminase levels in the serum of the mice [101]. Chen 
and Yu, 1993 [102], have reported that ganosporic acid A has shown 
significant activity of lowering the levels of GPT in mice with liver 
injury by carbon tetrachloride (CCL4) and exhibits hepatoprotective 
effect. Lin et al., 2003 [38], and Liu et al., 2014 [103], observed that 
triterpenoids such as GA XL, XL2, and ganoderic in from the extracts 
of G. lucidum and G. theaecolum have good hepatoprotective properties 
suppress the growth of hepatoma cells. Wu et al., 2016 [104], 
observed the hepatoprotective effects and mechanism of the action 
of triterpenoids from G. lucidum on α-amanitin-induced liver injury 
in mice. Wu et al., 2016 [105], studied the hepatoprotective effect 
of Ganoderma triterpenoids against oxidative damage induced by 
tert-butyl hydroperoxide in human hepatic cells. GAs, namely, GAs R 
and S, from the cultured mycelium of G. lucidum have shown strong 
hepatoprotective activity in galactosamine-induced cytotoxicity in 
cultured rat hepatocytes. The triterpenoid extracts from Ganoderma can 
prevent liver damage induced by CCL4 and galactosamine in rats [106]. 
The triterpenoids from G. lucidum have shown significant protection 
against immunological liver damage in mice in vitro and in vivo.
Neurotrophic activity
Several studies have confirmed the neuroprotective activity of 
triterpenoids from Ganoderma species [107-109]. Zhou et al., 2012 [109], 
reported neuroprotective effect of pre-administration of G. lucidum 
spores on rat hippocampus. Various studies have reported that the 
compounds, 4,4,14α-Trimethyl-5α-chol-7,9 (11)-diene-3-oxo-24-oic-
acid and methyl ganoderate B, have showed nerve growth factor-like 
neuronal survival-promoting effects [100,110], whereas the compounds 
4,4,14α-Trimethyl-5α-chol-7,9 (11)-diene-3-oxo-24-oic-acid, methyl 
ganoderate B, methyl ganoderate A, GA S1, and GA T-Q showed 
brain-derived neurotrophic factor-like neuronal survival-promoting 
activities [100,110-112]. Compounds such as n-butyl ganoderate H and 
methyl ganoderate A acetonide have shown specific antiacetylcholine 
terse activity and have been examined as possible drug candidates 
for the treatment of Alzheimer’s and other related neurodegenerative 
diseases. The compounds lucidadiol, ganodermanondiol, and other 
Ganoderma triterpenes have shown moderate acetylcholinesterase 
inhibitory activity [113]. These observations indicate that these 
lanostane triterpenes are potential inhibitors of acetylcholine esterase 
and may be considered as preferential drug candidates [114].
Anti-inflammatory potential
About 20% of the cancers are considered to be the result of 
inflammation [115,116]. The carcinogenesis is promoted due to 
the chronic overexpression of inflammatory cytokines such as IL-6, 
VEGF, and tumor necrosis factor-α [117,118]. The administration of a 
triterpene extract of G. lucidum is known to suppress the inflammatory 
cytokine secretion in macrophage cells, therefore, reducing the level of 
inflammation [119].
CONCLUSION
The beneficial health attributes of Ganoderma species are due to the 
presence of various bioactive compounds. Ganoderma genus, in general, 
and G. lucidum, in particular, can be considered as a natural pharmacy 
store besides being natural therapeutic machinery. There are two main 
groups of bioactive substances triterpenes and polysaccharides that 
have been studied in detail. Triterpenoids have been reported as having 
cytotoxic, hepatoprotective, anti-inflammatory, anti-HIV, neurotrophic, 
along with antitumor, anticancer, and antioxidant activities. In addition, 
because the various bioactive compounds isolated from G. lucidum 
27
Asian J Pharm Clin Res, Vol 12, Issue 4, 2019, 22-30
 Bhat et al. 
did not show any toxic side effects, the demand for this mushroom as 
health fortifying food, a natural remedy, and dietary food is increasing 
day by day and attracting the interests of the scientific community 
and industrial community as well. However, due to the lack of results, 
intense investigation needs to be performed in the field (e.g., human 
clinical trials). Till now, the available data suggest that G. lucidum 
has a high potential to be accepted as a good health food supplement 
for patients experiencing cancer therapy. This available knowledge 
and further investigation would facilitate the development of new 
nutraceuticals and pharmacological formulations.
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